NNNN
Anbio Biotechnology Class A Ordinary Shares
NASDAQ: NNNN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$25.35
-14.88% today
Updated 2026-06-05
Market cap
$684.26M
P/E ratio
103.93
P/S ratio
79.13x
EPS (TTM)
$0.15
Dividend yield
—
52W range
$9 – $56
Volume
0.0M
WallStSmart proprietary scores
52
out of 100
Grade: C
Hold
Investment rating
5.3
Growth
C+6.5
Quality
B9.5
Profitability
A+4.0
Valuation
C4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$0.68
-97.32%
12-Month target
$0.68
-97.32%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Profit margin 74.10% — above average
+ ROE 32.33% — strong efficiency
+ Revenue growth 73.90% QoQ
Risks
- Negative free cash flow $-6.74M
- P/E 103.93x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $23.54M | $6.71M | $8.19M | $9.76M | $8.65M |
| Net income | $10.01M | $2.25M | $2.37M | $7.23M | $3.04M |
| EPS | — | — | — | — | $0.15 |
| Free cash flow | $4.45M | $898367.00 | $2.08M | $-6.74M | $-6.74M |
| Profit margin | 42.52% | 33.58% | 28.99% | 74.06% | 74.10% |
Peer comparison
Smart narrative
Anbio Biotechnology Class A Ordinary Shares trades at $25.35. representing a P/E of 103.93x trailing earnings. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $8.65M. with profit margins at 74.10%.
Frequently asked questions
What is Anbio Biotechnology Class A Ordinary Shares's stock price?
Anbio Biotechnology Class A Ordinary Shares (NNNN) trades at $25.35, on a P/E of 103.9x and a P/S of 79.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Anbio Biotechnology Class A Ordinary Shares overvalued?
Anbio Biotechnology Class A Ordinary Shares carries a Smart Value Score of 52/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Anbio Biotechnology Class A Ordinary Shares (NNNN)?
The 12-month analyst consensus target is $0.68, about 97.3% below the current $25.35. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Anbio Biotechnology Class A Ordinary Shares's revenue?
Anbio Biotechnology Class A Ordinary Shares's trailing twelve-month revenue is $8.65M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio79.13x
ROE32.33%
Beta—
50D MA$27.12
200D MA$28.71
Shares out0.04B
Float0.04B
Short ratio—
Avg volume0.0M
Performance
1 week+0.00%
1 month-14.66%
3 months+5.36%
YTD-23.55%
1 year—
3 years—
5 years—